Today’s AI Top Pick: LRN

LRN is the clear pick here. Stride passes the screen with real fundamentals behind it: fwdPe of 11.46, PEG of 1.06, ROE of 20.14%, profit margin of 12.15%, sales growth of 10.93%, debtEq just 0.33, and an analyst recom of 1.4 with 40.8% target upside. The fundamental_score of 7 vs VERA's 2.5 is a chasm. Kronos bullish_prob is 1.0 and the screen already validated Model Hit Rate ≥55% and Model Edge (1d) ≥3%. The tape is constructive without being extended. On the 1h, current 86.07 sits at 66% of range with fc_short +4.72% and fc_long +7.36%. On the 1d, position in range is just 31.05% with a -6.47% drawdown from the 21-bar high — you're not chasing — and fc_long is +17.0%. The 4h and 1wk are softer (fc_long -8.58% and -24.32% respectively), so this isn't a perfect four-timeframe stack, but the daily forecast magnitude (+17%) and near-term 1h bullishness combined with a mid-range daily position is exactly the 'buy the dip in an uptrend' geometry the screen is designed to find. Recent news is a tailwind: three July 23 pieces frame LRN as a value opportunity after a price drop with 'platform issues behind it' and long-term growth ahead. That aligns with the -34.16% 1yr perf and +32.56% YTD — a name that took a hit, has stabilized, and is being re-rated. No dilution, no legal overhang, no short-seller report. VERA is a hard pass as the winner despite a 125% target upside and 23.11% short float. Kronos bullish_prob is 0, near-term is 0, the 1d forecast is -1.79% short / -10.86% mid, the 1wk fc_long is -35.95%, ROE is -71.32%, and there are no earnings, sales, or margin data. The FDA approval for TRUTAKNA on 7/11 is a real positive catalyst, but the model tape has decisively rejected it post-news — chasing an approval into a -35% weekly forecast with negative bullish_prob is not the trade. Today is the right entry for LRN because you're buying at 31% of daily range, not the top, with positive short-term momentum resuming and a fundamentally cheap stock.